EP 1300

Drug Profile

EP 1300

Alternative Names: EP1300; Malaria DNA vaccine - KAEL-GemVax

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institutes of Health (USA); Pharmexa-Epimmune
  • Developer KAEL-GemVax; National Institutes of Health (USA)
  • Class Antimalarials; DNA vaccines; Parasitic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Malaria

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Malaria(Prevention) in USA (Parenteral, Injection)
  • 19 Jan 2012 The National Institute of Allergy and Infectious Diseases completes enrolment in a phase I trial for Malaria in USA (NCT01169077)
  • 23 Sep 2010 Phase-I clinical trials in Malaria prevention in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top